1. Genetic inhibition of RIPK3 ameliorates functional outcome in controlled cortical impact independent of necroptosis
- Author
-
Limin Wu, Joon Yong Chung, Tian Cao, Gina Jin, William J. Edmiston, Suzanne Hickman, Emily S. Levy, Jordyn A. Whalen, Eliza Sophie LaRovere Abrams, Alexei Degterev, Eng H. Lo, Lorenzo Tozzi, David L. Kaplan, Joseph El Khoury, and Michael J. Whalen
- Subjects
Cytology ,QH573-671 - Abstract
Abstract Traumatic brain injury (TBI) is a leading cause of death and disability with no specific effective therapy, in part because disease driving mechanisms remain to be elucidated. Receptor interacting protein kinases (RIPKs) are serine/threonine kinases that assemble multi-molecular complexes that induce apoptosis, necroptosis, inflammasome and nuclear factor kappa B activation. Prior studies using pharmacological inhibitors implicated necroptosis in the pathogenesis of TBI and stroke, but these studies cannot be used to conclusively demonstrate a role for necroptosis because of the possibility of off target effects. Using a model of cerebral contusion and RIPK3 and mixed lineage kinase like knockout (MLKL −/−) mice, we found evidence for activation of RIPK3 and MLKL and assembly of a RIPK1-RIPK3-MLKL necrosome complex in pericontusional brain tissue. Phosphorylated forms of RIPK3 and MLKL were detected in endothelium, CD11b + immune cells, and neurons, and RIPK3 was upregulated and activated in three-dimensional human endothelial cell cultures subjected to CCI. RIPK3 −/− and MLKL −/− mice had reduced blood-brain barrier damage at 24 h (p
- Published
- 2021
- Full Text
- View/download PDF